Does interferon improve portal hypertension?

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 1, 2006, Pages 7-12

  Rincón, Diego ^a   Ripoll, Cristina ^a   Catalina, María Vega ^a   Salcedo, Magdalena ^a   Bañares, Rafael ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Antiviral therapy; Hepatic venous pressure gradient; Hepatitis C; Liver cirrhosis

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CILUPREVIR; COLCHICINE; INTERFERON; LAMIVUDINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN; TIMOLOL; UNCLASSIFIED DRUG; VX 950;

ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CAUSE OF DEATH; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ESOPHAGUS VARICES; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; SECONDARY PREVENTION; SURVIVAL RATE; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; HYPERTENSION, PORTAL; INTERFERONS;

EID: 33748050760     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl170     Document Type: Article

References (46)

1. Ghany MG, Kleiner DE, Alter H et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124: 97-104.
2. Liang TJ, Rehermann B, Seeff LB et al. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132: 296-305.
3. Bosch J, Garcia-Pagan JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol 2000; 32: 141-56.
4. Perello A, Escorsell A, Bru C et al. Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis. Hepatology 1999; 30: 1393-7.
5. Valla D, Bercoff E, Menu Y et al. Discrepancy between wedged hepatic venous pressure and portal venous pressure after acute propranolol administration in patients with alcoholic cirrhosis. Gastroenterology 1984; 86: 1400-3.
6. Lebrec D, Hillon P, Munoz C et al. The effect of propranolol on portal hypertension in patients with cirrhosis: A hemodynamic study. Hepatology 1982; 2: 523-7.
7. Garcia-Tsao G, Groszmann RJ, Fisher RL et al. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985; 5: 419-24.
8. Casado M, Bosch J, Garcia-Pagan JC et al. Clinical events after transjugular intrahepatic portosystemic shunt: Correlation with hemodynamic findings. Gastroenterology 1998; 114: 1296-303.
9. Moitinho E, Escorsell A, Bandi JC et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology 1999; 117: 626-31.
10. Merkel C, Bolognesi M, Sacerdoti D et al. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000; 32: 930-1.
11. Feu F, Garcia-Pagan JC, Bosch J et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995; 346: 1056-9.
12. Abraldes JG, Tarantino I, Turnes J et al. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003; 37: 902-8.
13. Villanueva C, Minana J, Ortiz J et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001; 345: 647-55.
14. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
15. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-65.
16. Strader DB, Wright T, Thomas DL et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-71.
17. Poynard T, McHutchison J, Manns M et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-13.
18. Shiratori Y, Imazeki F, Moriyama M et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517-24.
19. García-Tsao G, Rodríguez-Pérez F, Blei AT et al. Treatment with interferon reduces portal pressure in patients with chronic hepatitis C. A randomized placebo trial. Gastroenterology 1996; 10: A1193.
20. Valla DC, Chevallier M, Marcellin P et al. Treatment of hepatitis C virus-related cirrhosis: A randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology 1999; 29: 1870-5.
21. Rincón D, Ripoll C, Lo Iacono O et al. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and fibrosis stage 3 or 4. Am J Gastroenterol 2006, in press.
22. Groszmann RJ, Garcia-Tsao G, Bosch J et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005; 353: 2254-61.
23. Afdhal N, Freilich B, Levine R et al. Colchicine versus PEG-Intron long term (COPILOT) trial: Interim analysis of clinical outcomes at year 2. Hepatology 2004; 40 Suppl 1: 239A.
24. Burroughs AK, Groszmann R, Bosch J et al. Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: Is hepatic venous pressure gradient a better end point? Gut 2002; 50: 425-7.
25. Everson GT, Trotter J, Forman L et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255-62.
26. Forns X, Garcia-Retortillo M, Serrano T et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389-96.
27. Thomas RM, Brems JJ, Guzman-Hartman G et al. Infection with chronic hepatitis C virus and liver transplantation: A role for interferon therapy before transplantation. Liver Transpl 2003; 9: 905-15.
28. Crippin JS, McCashland T, Terrault N et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8: 350-5.
29. Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9: S1-9.
30. Mallat A, Preaux AM, Blazejewski S et al. Interferon alfa and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatology 1995; 21: 1003-10.
31. Ratti L, Pozzi M, Bosch J. Pathophysiology of portal hypertension in HCV-related cirrhosis. Putative role of assessment of portal pressure gradient in Peginterferon-treated patients. Dig Liver Dis 2005; 37: 886-93.
32. Lohmann V, Korner F, Koch J et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-3.
33. Bartenschlager R, Ahlborn-Laake L, Mous J et al. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J Virol 1993; 67: 3835-44.
34. Grakoui A, Wychowski C, Lin C et al. Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol 1993; 67: 1385-95.
35. Hinrichsen H, Benhamou Y, Wedemeyer H et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004; 127: 1347-55.
36. Mast EE, Alter MJ, Margolis HS. Strategies to prevent and control hepatitis B and C virus infections: A global perspective. Vaccine 1999; 17: 1730-3.
37. McQuillan GM, Coleman PJ, Kruszon-Moran D et al. Prevalence of hepatitis B virus infection in the United States: The National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999; 89: 14-8.
38. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-8.
39. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-63.
40. Schalm SW, Heathcote J, Cianciara J et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial. Gut 2000; 46: 562-8.
41. Goodman Z, Dhillon A, Wu P et al. Lamivudine treatment reduces progression to cirrhosis in patients with chronic hepatitis B (abstr). J Hepatol 1999; 30 Suppl 1: 59.
42. Dienstag JL, Goldin RD, Heathcote EJ et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124: 105-17.
43. Lau GK, Piratvisuth T, Luo KX et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.
44. Fontana RJ, Hann HW, Perrillo RP et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123: 719-27.
45. de Jongh FE, Janssen HL, de Man RA et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103: 1630-5.
46. Weissberg JI, Andres LL, Smith CI et al. Survival in chronic hepatitis B. An analysis of 379 patients. Ann Intern Med 1984; 101: 613-6.